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Abstract
In a prospective study (2009–2011) in healthcare institutions from
the Canary Islands (Spain), 6 out of 298 carbapenem non-
susceptible Pseudomonas aeruginosa isolates produced a metallo-b-
lactamase: four IMP-15, two VIM-2 (including one IMP-15-positive
isolate) and one VIM-1. Multilocus sequence typing identiﬁed the
single VIM-1-producing isolate as clone ST111 and two IMP-15-
producing isolates as ST606, but, strikingly, bacterial re-identiﬁca-
tion revealed that the other three isolates (producing IMP-15 and/
or VIM-2) were actually Pseudomonas putida. Further retrospective
analysis revealed a very high prevalence (close to 50%) of
carbapenem resistance in this environmental species. Hence, we
report the simultaneous emergence in hospitals on the Canary
Islands of P. putida and P. aeruginosa strains producing IMP-15, a
metallo-b-lactamase not previously detected in Europe, and
suggest an underestimated role of P. putida as a nosocomial
reservoir of worrying transferable resistance determinants.
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Pseudomonas aeruginosa is one of the most relevant nosocomial
pathogens, particularly in the Intensive Care Unit setting [1], as
well as the ﬁrst cause of chronic respiratory infections in
patients with underlying diseases such as cystic ﬁbrosis [2].
One of the most striking features of this pathogen is its
outstanding capacity for the development of antimicrobial
resistance, through the selection of chromosomal mutations
and the acquisition of horizontally transferred resistance
determinants in genetic elements such as integrons located
in transposons and/or plasmids. Particularly noteworthy
among these determinants are class B carbapenemases (also
called metallo-b-lactamases: MBLs), hydrolysing all b-lactams
with the exception of monobactams [3–5]. In this scenario, the
prevalence of multidrug-resistant and extensively drug-resis-
tant P. aeruginosa strains is globally increasing, signiﬁcantly
compromising our anti-pseudomonal arsenal [6]. Moreover,
recent reports have provided evidence of the existence of
multidrug-resistant/extensively drug resistant clones dissemi-
nated in several hospitals worldwide and for that reason
denominated high-risk clones [7]. Among them, ST235, ST111
and ST175 are probably more widespread, linked to multiple
transferable and mutational resistance mechanisms [8]. Fur-
thermore, although some environmental Pseudomonas species
such as Pseudomonas putida may not have the clinical relevance
of P. aeruginosa, their potential role as reservoirs of transfer-
able b-lactamases has recently been suggested [9,10]. In this
work, we report the simultaneous emergence of P. putida and
P. aeruginosa strains harbouring an MBL not previously
detected in Europe (IMP-15), and highlight the potentially
underestimated role of P. putida as a nosocomial reservoir of
worrying transferable resistance determinants.
A prospective study, from 2009 to 2011, was carried out to
determine the prevalence of carbapenem non-susceptible
P. aeruginosa in healthcare institutions of Gran Canaria, Canary
Islands (Spain), including Hospital Universitario de Gran
Canaria Dr Negrın, Hospital Universitario Materno Infantil
and the primary-care centres. The P. aeruginosa isolates
showing an intermediate or resistant clinical category (follow-
ing CLSI breakpoints) to at least one of the tested carbapen-
ems (imipenem and meropenem) were included [11]. The GN
card of Vitek2 (bioMerieux, Marcy l’Etoile, France) was used
for initial identiﬁcation and susceptibility testing. From a total
of 298 non-susceptible isolates (14.7% of all the P. aeruginosa
isolates recovered in the study period), six yielded a positive
result with the MBL-Etest (bioMerieux). To conﬁrm the
presence of MBL determinants and determine the speciﬁc
genes involved, PCR followed by sequencing of the complete
coding regions was performed using previously described
primers and protocols [12,13]. Sequencing results revealed the
presence of blaIMP-15 in four isolates, blaVIM-2 in two (including
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one of the blaIMP-15-positive isolates) and blaVIM-1 in one.
Strikingly, the re-identiﬁcation using the Api-20NE strips
(bioMerieux) and 16S rDNA sequencing showed that three
of the six isolates (producing blaVIM-2 and/or blaIMP-15) were
actually P. putida.
Clonal relatedness was evaluated by pulsed-ﬁeld gel elec-
trophoresis (PFGE) following described protocols [13]. Addi-
tionally, P. aeruginosa isolates were further analysed through
multilocus sequence typing (MLST), using described proce-
dures and available databases (http://pubmlst.org/paerugin
osa/). The PFGE, MLST and resistance proﬁles (imipenem,
meropenem, ceftazidime, cefepime, aztreonam, piperacillin-
tazobactam, amikacin, gentamicin, tobramycin, colistin and
ciproﬂoxacin MICs determined by Etest) documented for the
six isolates are shown in Table 1. The single VIM-1-producing
P. aeruginosa isolate was found to belong to the internationally
spread high-risk clone ST111, previously linked to multiple
different integron-borne acquired b-lactamases, from narrow
to extended spectrum and carbapenemases [14]. Although
VIM-2 production has been recently linked to ST111 in several
Spanish hospitals [8], this is the ﬁrst association of this clone
with VIM-1 in our territory. On the other hand, the two
P. aeruginosa isolates producing blaIMP-15 showed an identical
PFGE pattern, identiﬁed as ST606 clone through MLST
(Table 1). ST606 has been reported in a few P. aeruginosa
isolates [15], but has never been related to an acquired b-
lactamase, and it is not yet considered one of the high-risk
clones [7]. Interestingly, one of the two isolates was recovered
from a sputum sample of a patient with cystic ﬁbrosis,
accounting for the ﬁrst documentation of colonization by MBL-
producing P. aeruginosa among Spanish cystic ﬁbrosis patients
(Table 1). The two IMP-15-producing P. putida isolates also
belonged to a single clone, showing an identical PFGE pattern
(despite one of the isolates additionally produced VIM-2),
completely different to that of the remaining VIM-2-producing
strain (Table 1). Additionally, the three P. putida isolates were
found to be aztreonam resistant. As shown in Table 1, MICs
performed in M€uller–Hinton plates containing the efﬂux pump
inhibitor Phe-Arg b-naphthylamide dihydrochloride (ﬁnal con-
centration, 20 mg/L) [16] suggested the involvement of efﬂux
in the resistance phenotype.
The re-identiﬁcation of three of the six isolates as P. putida
prompted us to retrospectively review the carbapenem-
resistance rates in this species during the study period,
yielding quite alarming results: up to 22 of 48 isolates (45.8%)
were found to be carbapenem resistant. Moreover, carbape-
nem resistance in P. putida signiﬁcantly increased during the
study period reaching 71.4% (10 of 13) in 2011. Unfortunately,
a screening for MBL production in the 22 isolates could not be
performed retrospectively because the isolates were no longer T
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available, but the resistance patterns of many of them suggest a
high prevalence of MDR determinants that could be trans-
ferred to P. aeruginosa, which is consistent with previous
evidence [17].
This is the ﬁrst time that blaIMP-15 has been detected in
Europe, as well as, to our knowledge, the ﬁrst report of the
simultaneous presence of VIM and IMP enzymes in P. putida
isolates. IMP-15, showing a 90% identity with IMP-1, was
originally detected in a P. aeruginosa strain from Thailand
(GenBank accession no. AY553333), and later in a strain
recovered from a surgical wound of a patient admitted to a US
hospital after surgery in a Mexican centre [18]. Other reports
have documented an endemic presence in Mexico of P. aeru-
ginosa strains harbouring blaIMP-15 in several integron struc-
tures related to In95 [19–21]. To analyse whether blaIMP-15 of
the strains from the Canary Islands were located in the same
genetic element, PCR and sequencing of the complete integron
was performed following described protocols [13]. However,
a different integron structure (designated In589, GenBank
accession no. KC310496), which contained blaIMP-15 and
blaOXA-4, was detected, arguing against a direct importation
of the Mexican P. aeruginosa strains. Finally, regarding the
potential plasmid/chromosomal location of blaIMP-15 in the
studied strains, all attempts to transfer the plasmid DNA
(obtained using the Ultraclean Plasmid Prep Kit; MO BIO
Laboratories Inc., Carlsbad, CA, USA) to the PAO1 reference
strain through electroporation/conjugation yielded negative
results. Furthermore, the southern blot hybridization following
described protocols [10] and using the North2South Com-
plete Biotin Random Primer labelling and detection kit
(Thermo Scientiﬁc, Rockford, IL, USA), over the I-CeuI/S1
nuclease-digested genomes, suggested the chromosomal loca-
tion of blaIMP-15 in all the strains, given that the blaIMP-15 probe
hybridized with bands that also hybridized with the rRNA gene
probe (data not shown).
In summary, we report the simultaneous emergence in
hospitals from the Canary Islands of P. putida and P. aeruginosa
strains producing IMP-15, an MBL not previously detected in
Europe. Moreover, our results suggest a relevant role of
P. putida as a nosocomial reservoir of worrying transferable
resistance determinants, which is probably underestimated
because of the lack of active surveillance in environmental
Pseudomonas species and their misidentiﬁcation as P. aeruginosa.
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